Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Britain

Roche Basel Switzerland

Roche’s lung cancer drug Alecensa wins EU approval

Monotherapy conditionally approved as second-line NSCLC treatment

- PMLiVE

2016: The year when deal-makers took stock?

Merger-mania and asset swaps slowed and joint ventures were back in fashion

- PMLiVE

New guide to improve cancer control published in EU

Outlines recommendations to boost quality of life and reduce financial burden

Eli Lilly HQ

Lilly claims first place for JAK inhibitor Olumiant in EU

EMA approves once-daily rheumatoid arthritis drug ahead of Pfizer’s Xeljanz

- PMLiVE

Innovation and the pharma patent court

As the UK prepares to exit the European Union a unified patent system is still essential

- PMLiVE

Dr Reddy’s brings its generics portfolio to France

Continues the European roll-out of its oncology and anti-infective products

- PMLiVE

Denmark pitches for EMA, with help from ex Novo Nordisk CEO

Lars Rebien Sørensen to serve as special envoy to promote Danish candidacy

- PMLiVE

Promoting off-label use: where to draw the line?

Looking at the trend among EU member states to actively promote the off-label use of medicines

- PMLiVE

Amgen’s Humira biosimilars backed for EU approval

Amgevita and Solymbic prepare to challenge AbbVie’s blockbuster

UK flag

Life sciences to play key role in UK’s post-Brexit strategy

Prime minister unveils plans to boost jobs, growth and commercialise country’s science base

- PMLiVE

A rare talent

Shire’s Sebastian Stachowiak on dealing with change and working for a fit-for-purpose orphan drug environment

Sanofi reception

Sanofi wins EU approval for new diabetes combination Suliqua

European Commission licenses the once-daily version of Lantus and Lyxumia

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links